Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.
Zhang Y, Zhou H, Suo S, Zhuang J, Yang L, He A, Liu Q, Du X, Gao S, Li Y, Li Y, Chen Y, Wu W, Zhu H, He G, Hong M, Jiang Q, Jiang Z, Jing H, Wang J, Xu N, Yue L, Zheng C, Zhou Z, Jin C, Li X, Liu L, Xu Y, Wu D, Zhang F, Zhang J, Wu L, Yin H, Lv B, Xiao Z, Jin J. Zhang Y, et al. Among authors: zhuang j. Blood Cancer J. 2024 Dec 18;14(1):216. doi: 10.1038/s41408-024-01202-8. Blood Cancer J. 2024. PMID: 39695117 Free PMC article. Clinical Trial.
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yu W, Jin J. Zhang Y, et al. Among authors: zhuang j. Am J Hematol. 2022 Dec;97(12):1510-1519. doi: 10.1002/ajh.26709. Epub 2022 Oct 4. Am J Hematol. 2022. PMID: 36054786 Free PMC article. Clinical Trial.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y, Zhou H, Jiang Z, Wu D, Zhuang J, Li W, Jiang Q, Wang X, Huang J, Zhu H, Yang L, Du X, Li F, Xia R, Zhang F, Hu J, Li Y, Hu Y, Liu J, Jin C, Sun K, Zhou Z, Wu L, Yin H, Suo S, Yu W, Jin J. Zhang Y, et al. Among authors: zhuang j. Am J Hematol. 2024 Apr;99(4):774-779. doi: 10.1002/ajh.27245. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343062 Clinical Trial.
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H, Yin Q, Jin J, Liu T, Cai Z, Jiang B, Li D, Sun Z, Li Y, He Y, Ma L, Gao S, Hu J, He A, Du X, Liu D, Zhang X, Ke X, Zhuang J, Han Y, Wang X, Chen Y, Gordon P, Yu D, Zugmaier G, Wang J. Zhou H, et al. Among authors: zhuang j. Hematology. 2022 Dec;27(1):917-927. doi: 10.1080/16078454.2022.2111992. Hematology. 2022. PMID: 36000952 Free article.
Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D, Shi H, Liu X, Duan M, Zhuang J, Du X, Qin L, Hui W, Liang R, Wang M, Chen Y, Li D, Yang W, Tang G, Zhang W, Kuang X, Su W, Han Y, Chen L, Xu J, Liu Z, Huang J, Zhao C, Tong H, Hu J, Chen C, Chen X, Xiao Z, Jiang Q. Shi D, et al. Among authors: zhuang j. Leuk Lymphoma. 2021 Nov;62(11):2703-2715. doi: 10.1080/10428194.2021.1933481. Epub 2021 Jun 8. Leuk Lymphoma. 2021. PMID: 34098836
[Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M, Shi DY, Shi HX, Liu XL, Duan MH, Zhuang JL, Du X, Qin L, Hui WH, Liang R, Wang MF, Chen Y, Li DY, Yang W, Tang GS, Zhang WH, Kuang X, Su W, Han YQ, Chen LM, Xu JH, Liu ZG, Huang J, Zhao CT, Tong HY, Hu JD, Chen CY, Chen XQ, Xiao ZJ, Jiang Q. Bao M, et al. Among authors: zhuang jl. Zhonghua Xue Ye Xue Za Zhi. 2021 Dec 14;42(12):985-992. doi: 10.3760/cma.j.issn.0253-2727.2021.12.004. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 35045668 Free PMC article. Chinese.
[The 505th case: refractory ascites and monoclonal immunoglobulin].
Zhang FJ, Zheng WY, Wang X, Jiang XY, Zhuang JL. Zhang FJ, et al. Among authors: zhuang jl. Zhonghua Nei Ke Za Zhi. 2024 May 1;63(5):517-520. doi: 10.3760/cma.j.cn112138-20231208-00373. Zhonghua Nei Ke Za Zhi. 2024. PMID: 38715493 Chinese.
Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L, Wang YT, Liu P, Lu MQ, Zhuang JL, Zhang M, Xia ZJ, Li ZL, Yang Y, Yan ZY, Jing HM, Dong F, Chen WM, Wu Y, Zhou HB, Fu R, Gong YP, Huang WR, Zhang YQ. Bao L, et al. EClinicalMedicine. 2024 Jan 25;68:102431. doi: 10.1016/j.eclinm.2024.102431. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38318126 Free PMC article.
3,470 results